News

NDF’s Stuart Roberts Initiates Cynata Research Coverage

With 11 reasons to consider Cynata Therapeutics and an expected total share holder return of 331%, NDF sees a price target of $2.00 per share based on a probability-weighted valuation model.

Cynata report from NDF Research